Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 December 2007

Therapeutic drug monitoring of tacrolimus

P. Wallemacq

Ann Transplant 2008; 13(1): 25-25 :: ID: 880179

Abstract

The purpose of this work is to summarize the current trends in tacrolimus (TAC) optimisation in transplant patients. Knowledge of the analytical method used to monitor TAC is mandatory (cross-reactivity, interferences, calibration bias, reproducibility, sensitivity, ...). Even more important is the ability to draw comparison among the different methods available (patients outcome according to TAC blood levels, multicenter clinical trials, ...). The choice of the analytical method should depend upon each laboratory characteristics (number of samples, staff experience, equipment, ...), and on the experience of clinicians with a particular method. Even though the vast majority of laboratories use immunoassays, implementation of LC-MS(MS) is increasing (2% in 1999, 19% in 2007). A large discussion exists about the most accurate approach to evaluate drug exposure or AUC (single time point -C0 or others-, limited sampling strategy or Bayesian estimates, ...). Most multi-centre trials (e.g. SYMPHONY study) stress the importance of concomitant therapies, time post-transplantation and transplant type, in defining appropriate TAC target concentrations. Recent data suggest a reduction in the recommended target TAC concentration down to 3-7 ng/mL when the drug is associated to daclizumab, MMF and steroids. Treatment management should also most likely take advantage of integrating the genetic polymorphism of proteins or enzymes involved in the tacrolimus drug disposition, in order to reach earlier optimal dosage regimen. TAC blood concentrations clearly correlate with the risk of side effects, whereas the relationship with efficacy seems much weaker. Research protocols are currently ongoing precisely to improve the predictability of the treatment efficacy (pharmacodynamic markers, drug concentration within target tissue, ...).

Keywords: cross-reactivity, biothecnology, proteomes

0 Comments

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358